anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This invention relates to novel anthraquinone compounds useful in the treatment of allergic, inflammatory conditions, tumor conditions and therapeutic compositions containing such compounds. That compounds of 1,5-bis-substituted anthraquinone compounds according to formula I and II. Wherein R represents the groups select from 1 to 10 carbon atoms alkoxyl group, alkyl group, alkylamine group, alkoxylamine group, or alkoxyl substituted phenyl group, alkoxyl substituted benzyl group, alkyl substituted phenyl group, alkyl substituted benzyl group, alkylamine substituted phenyl group, alkylamine substituted benzyl group, alkoxylamine substituted phenyl group, or alkoxylamine substituted benzyl group. More then one halogen group substituted on the alkyl group, alkoxyl group, benzyl group, or phenyl group. The side alkoxyl group and alkyl group are select from a straight or branched chain. The halogen group represents R Cl, Br I.
Participants will receive bilateral, behind-the-ear hearing aids as part of this study. The intervention will involve e-Audiology sessions following the initial hearing aid fitting and orientation. E-Audiology sessions will consist of hearing aid follow-up programming, troubleshooting, HAT assistance, and general help with hearing devices. E-Audiology sessions will take place over the course of approximately 6 weeks.
This protocol is designed to provide a mechanism for the Department of Transfusion Medicine (DTM), Clinical Center (CC) to collect and process blood components from paid, healthy volunteer donors for distribution to NIH intramural Investigators and FDA researchers for in vitro laboratory use. Donors meeting research donor eligibility criteria will be recruited to donate blood and blood components by standard phlebotomy and apheresis techniques. The investigational nature of the studies in which their blood will be used, and the risks and discomforts of the donation process, will be carefully explained to the donors, and a signed informed consent document will be obtained. Donors will be compensated according to an established schedule, based on the duration and discomfort of their donation. NIH and FDA Investigators requesting blood components for research use will be required to submit an electronic (web-based) memo of request, briefly describing the nature of the research, and providing assurance that samples provided through this protocol will be used solely for in vitro and not for in vivo research. This protocol also provides a detailed schema for careful and frequent laboratory safety monitoring of repeat research apheresis donors.

Blood components for research use will be distributed with a unique product number, and the DTM Principal and Associate Investigators will serve as the custodians of the code that links the product with the donor s identity. The nature of the in vitro studies in which the blood and components collected on this study will be used is not the subject of this protocol, and is not possible to describe since it involves basic investigative efforts in greater than multiple different NIH and FDA laboratories. The intent of this protocol is not to approve the research itself, but to provide adequate and complete informed consent for the donor, and to assure that the education, counseling, and protection of the study subjects (research blood donors) are performed in accordance with the Institutional Review Board (IRB), the Office of Human Subjects Research Protection (OHSRP), and other applicable Federal regulatory standards.
Hypertension is a very common disease, affecting approximately 65 million people in the United States. As many as 30 % of people with hypertension, approximately 20 million individuals, remain undiagnosed. As many as one third of patients seen in ED were noted to have elevated BP readings in prior studies. Approximately 5% of emergency department (ED) patients have severely elevated blood pressure. Prior studies suggest that as many as two thirds of ED patients with elevated BP can benefit from further therapy or closer clinic follow-up. However primary care follow-up after ED discharge with an elevated BP is surprisingly low. The purpose of this study is to measure the follow-up rate after the ED visit in individuals identified with elevated blood pressure after a brief counseling regarding risks of elevated blood pressure.
1. A chimeric isoprenoid synthase comprising a domain from a first isoprenoid synthase joined to a domain from a second, different isoprenoid synthase, whereby said chimeric isoprenoid synthase catalyzes the production of an isoprenoid reaction product that is not produced in the absence of said domain from said second, different isoprenoid synthase. 2. The chimeric isoprenoid synthase of Claim 1, wherein said chimeric isoprenoid synthase catalyzes at least two different isoprenoid reaction products. 3. The chimeric isoprenoid synthase of Claim 1, wherein said domain from said second, different isoprenoid synthase comprises a ratio determinant domain of said chimeric isoprenoid synthase. 4. The chimeric isoprenoid synthase of Claim 1, wherein said chimeric isoprenoid synthase is chosen from the group consisting of (a) the tobacco-Hyoscyamus CH4 chimeric isoprenoid synthase; (b) the tobacco-Hyoscyamus CH10 chimeric isoprenoid synthase; (c) the tobacco-Hyoscyamus CH11 chimeric isoprenoid synthase; (d) the tobacco-Hyoscyamus CH12 chimeric isoprenoid synthase; (e) the tobacco-Hyoscyamus CH13 chimeric isoprenoid synthase; and (f) the tobacco-Hyoscyamus CH14 chimeric isoprenoid synthase. 5. The chimeric isoprenoid synthase of Claim 1, wherein said chimeric isoprenoid synthase catalyzes the production of an antifungal agent. 6. The chimeric isoprenoid synthase of Claim 1, wherein said chimeric isoprenoid synthase catalyzes the production of an antibacterial agent. 7. The chimeric isoprenoid synthase of Claim 1, wherein said chimeric isoprenoid synthase catalyzes the production of an antitumor agent. 8. The chimeric isoprenoid synthase of Claim 1, wherein said domain from said first isoprenoid synthase is from a plant isoprenoid synthase and said domain from said second, different isoprenoid synthase is from a plant isoprenoid synthase. 9. The chimeric isoprenoid synthase of Claim 3, wherein said ratio-determinant domain of said chimeric isoprenoid synthase determines the ratio of isoprenoid reaction products of said chimeric isoprenoid synthase. 10. DNA encoding a chimeric isoprenoid synthase of Claim 1. 11. An expression vector containing the DNA of Claim 10. 12. A cell line containing the DNA of Claim 10 used for the production of chimeric isoprenoid synthase as claimed in Claim 1. 13. The cell line of Claim 10, wherein said cell line is Escherichia coli. 14. A method for producing a chimeric isoprenoid synthase, said method comprising:  (a) providing a cell line containing the DNA of Claim 10 positioned for chimeric isoprenoid synthase expression in said cell;  (b) culturing said cells under conditions for expressing said chimeric isoprenoid synthase, and  (c) recovering said chimeric isoprenoid synthase from said cells or cultural medium.
Two placebo-controlled, double-blind trials (Studies 1 and 2) were conducted in patients with AIS. Both studies enrolled patients with measurable neurological deficit who could complete screening and begin study treatment within 3 hours from symptom onset. A cranial computerized tomography (CT) scan was performed prior to treatment to rule out the presence of intracranial hemorrhage. Blood pressure was actively controlled (185/110 mm Hg or lower) for 24 hours.

Patients were randomized (1:1) to receive either 0.9 mg/kg Activase (maximum of 90 mg) or placebo. Activase was administered as a 10% initial IV bolus over 1 minute followed by continuous IV infusion of the remainder over 60 minutes. Study treatment was initiated prior to the availability of coagulation study results in patients without recent use of oral anticoagulants and/or heparin and was discontinued if the pretreatment prothrombin time (PT) was greater than 15 seconds or the activated partial thromboplastin time (aPTT) was elevated. Patients with prior aspirin use were included. Administration of anticoagulants and antiplatelet agents was prohibited for the first 24 hours following symptom onset.

Study 1 (n=291) evaluated neurological improvement at 24 hours after stroke onset. The primary endpoint, the proportion of patients with a 4 point or greater improvement in the National Institutes of Health Stroke Scale (NIHSS) score or complete recovery (NIHSS score of 0), was not significantly different between treatment groups. A prespecified secondary analysis suggested improved 3-month outcome associated with Activase treatment using the following stroke assessment scales: Barthel Index, Modified Rankin Scale, Glasgow Outcome Scale, and the NIHSS.

Study 2 (n=333) assessed clinical outcome at 3 months. A favorable outcome was defined as minimal or no disability using four stroke assessment scales: Barthel Index (score of 95 or greater), Modified Rankin Scale (score of 1 or less), Glasgow Outcome Scale (score of 1), and NIHSS (score of 1 or less). The results comparing Activase- and placebo-treated patients for the four outcome scales together (Generalized Estimating Equations) and individually are presented in Table 7. In this study, depending upon the scale, the favorable outcome of minimal or no disability occurred in at least 11 per 100 more patients treated with Activase than those receiving placebo. Study results demonstrated consistent functional and neurological improvement within all four stroke scales as indicated by median scores. These results were consistent with the 3-month outcome treatment effects observed in Study 1.

In a prespecified subgroup analysis of patients receiving aspirin prior to onset of stroke symptoms, the favorable outcome for Activase-treated patients was preserved.
The invention relates to the isolation and cloning of the structural gene, hipP, for the NTHi pili serotype 5 and the LKP operon. The invention relates to DNA molecules capable of hybridizing to the DNA sequences of the Haemophilus influenzae genome related to the pili. The invention further relates to a DNA molecule which encodes a pili protein, particularly a tip adhesin protein. The DNA molecules of the invention can be used in a method for assaying a sample, such as a blood sample, for the presence of Haemophilus influenzae in the sample. Accordingly, the invention further relates to the use of the DNA molecules as a diagnostic. The invention also relates to a recombinant Haemophilus influenzae pili protein, such as a tip adhesin protein. The protein can be employed in a method for immunizing an animal, such as a human, as a therapeutic or diagnostic.
BACKGROUND: Hyperuricemia has been shown to be an inducer of pro-inflammatory mediators by human primary monocytes. To study the deleterious effects of hyperuricemia, a reliable and stable in vitro model using soluble urate is needed. One recent report showed different urate-dissolving methods resulted in either pro-inflammatory or anti-inflammatory properties. The aim of this study was to compare the effect of two methods of dissolving urate on both primary human peripheral blood mononuclear cells (PBMCs) and THP-1 cells. The two methods tested were 'pre-warming' and 'dissolving with NaOH'.
METHODS: Primary human PBMCs and THP-1 cells were exposed to urate solutions, prepared using the two methodologies: pre-warming and dissolving with NaOH. Afterwards, cells were stimulated with various stimuli, followed by the measurement of the inflammatory mediators IL-1β, IL-6, IL-1Ra, TNF, IL-8, and MCP-1.
RESULTS: In PBMCs, we observed an overall pro-inflammatory effect of urate, both in the pre-warming and the NaOH dissolving method. A similar pro-inflammatory effect was seen in THP-1 cells for both dissolving methods after restimulation. However, THP-1 cells exhibited pro-inflammatory profile with exposure to urate alone without restimulation. We did not find MSU crystals in our cellular assays.
CONCLUSIONS: Overall, the urate dissolving methods do not have critical impact on its inflammatory properties. Soluble urate prepared using either of the two methods showed mostly pro-inflammatory effects on human primary PBMCs and monocytic cell line THP-1. However, human primary PBMCs and the THP-1 differ in their response to soluble urate without restimulation.
Intestinal tuft cells (TCs) are defined as chemosensory cells that can "taste" danger and induce immune responses. They play a critical role in gastrointestinal parasite invasion, inflammatory bowel diseases and high-fat diet-induced obesity. Intestinal IL-25, the unique product of TCs, is a key activator of type 2 immunity, especially to promote group 2 innate lymphoid cells (ILC2s) to secret IL-13. Then the IL-13 mainly promotes intestinal stem cell (ISCs) proliferation into TCs and goblet cells. This pathway formulates the circuit in the intestine. This paper focuses on the potential role of the intestinal TC, ILC2 and their circuit in obesity-induced intestinal damage, and discussion on further study and the potential therapeutic target in obesity.
NEW MATERIAL:A substance 301 expressed by formula I (both R1 and R2 are H or R1 is methyl and R2 is H, formula II or III) and salt thereof having the following physico-chemical properties (provided that R1 is methyl and R2 is H); Basic substance which is red powder. Molecular formula; C35H44O12. Molecular weight; 684 (measurd by the mass spectrometry). Solubility; Readily soluble in water and methanol, slightly soluble in chloroform and insoluble in diethyl ether and hexane, etc. USE:A carcinostatic agent and antimicrobial agent. PREPARATION:For example, a microorganism, belonging to the genus Streptomyces and capable of producing substance 301 (FERM-P No.789) is cultivated in an ordinary liquid culture medium, preferably at 15-37 deg.C normally for 50-100hr by the spinner culture method with aeration.
AIMS: Adiponectin is an adipocyte-derived circulating protein that exerts cardiovascular and metabolic protection. Due to the futile degradation of endogenous adiponectin and the challenges of exogenous administration, regulatory mechanisms of adiponectin biosynthesis are of significant pharmacological interest.
METHODS AND RESULTS: Here, we report that 5-diphosphoinositol 1,2,3,4,6-pentakisphosphate (5-InsP7) generated by inositol hexakisphosphate kinase 1 (IP6K1) governed circulating adiponectin levels via thiol-mediated protein quality control in the secretory pathway. IP6K1 bound to adiponectin and DsbA-L and generated 5-InsP7 to stabilize adiponectin/ERp44 and DsbA-L/Ero1-Lα interactions, driving adiponectin intracellular degradation. Depleting 5-InsP7 by either IP6K1 deletion or pharmacological inhibition blocked intracellular adiponectin degradation. Whole-body and adipocyte-specific deletion of IP6K1 boosted plasma adiponectin levels, especially its high molecular weight forms, and activated AMPK-mediated protection against myocardial ischaemia-reperfusion injury. Pharmacological inhibition of 5-InsP7 biosynthesis in wild-type but not adiponectin knockout mice attenuated myocardial ischaemia-reperfusion injury.
CONCLUSION: Our findings revealed that 5-InsP7 is a physiological regulator of adiponectin biosynthesis that is amenable to pharmacological intervention for cardioprotection.
Outpatient hysteroscopy is nowadays a commonly used procedure in Gynaecology in order to evaluate the uterine cavity and to diagnose different intrauterine diseases. It is a safe, convenient and cost-effective procedure in aiding the management of abnormal uterine bleeding. However, outpatient hysteroscopy can be associated with significant pain which would have impact on the woman's satisfaction and pain is one of the most common reasons for failure of the procedure.

Listening to music could be an easy and non-invasive way to reduce pain. A meta-analysis conducted on the effects of music on pain revealed that music interventions had statistically significant effects in decreasing pain on 0-10 pain scales. Researches on this topic in gynaecological office procedures, however, showed variation in the results. Some showed no positive effect of music on patient's level of pain, anxiety or satisfaction of patient or doctor for office hysteroscopy and colposcopy. On the other hand, some studies showed a positive effect of the use of music with a reduction of pain and anxiety during office hysteroscopy.
PROBLEM TO BE SOLVED: To enable a doctor to efficiently gather information by displaying retrieved medical treatment information by a means for display by medical treatment stages according to an inputted medical treatment stage. SOLUTION: A control process means 12 has a medical treatment stage input processing means 120, a processing means 121 for retrieval by medical treatment stages, and a processing means 122 for display by the medical treatment stages. The medical treatment stage input processing means 120 acquires a medical treatment state inputted by a user. Here, the medical treatment stage indicates stages of medical treatments done by a doctor for a patient from initial consultation to curing and are screening, discriminatory diagnosis, determinative diagnosis, passage observation, etc. Thus, the purpose of medical treatment is different among the respective stages, so the contents of information that the doctor requires vary.  For the purpose, the processing means 121 for retrieval by the medical treatment stages performs retrieval from a data base for medical treatment information by the medical treatment stages according to the inputted medical treatment stage and extracts medical treatment information corresponding to the medical treatment stage.
Chronic pancreatitis（CP）is a chronic progressive fibro-inflammatory disease of the pancreas induced by a wide range of factors including genetic and environmental elements, with recurrent abdominal pain and pancreatic secretion insufficiency as its major clinical signs. Chronic pancreatitis is not only a tough disease of the gastrointestinal system but also a worldwide medical problem. At present, the MESS (medicine-extracorporeal shock wave lithotripsy-endoscopic retrograde cholangiopancreatography-surgery）formed by changhai hospital in CP diagnosis and treatment is gradually becoming mature, and the clinical effect of this system is obvious. However, there are still some difficulties and knowledge gaps in the clinical treatment of CP. Currently, it is recommended by both domestic and foreign guidelines that ERCP combined with ESWL as the first-line treatment pattern for patients with chronic pancreatitis associate pain. It has previously been observed that ERCP performed less than 2 days after ESWL may be more likely to fail, possibly owing to ESWL-induced edema. However, there is no high-quality research to demonstrate how to choose the most optimal timing of ERCP after ESWL for patients with indications for endoscopic treatment. This prospective, randomized controlled research has therefore aimed to determine the most optimal timing of ERCP after ESWL. Patients with painful chronic pancreatitis and pancreatic stones larger than 5 mm in diameter will be randomly and equally assigned to two groups, which are divided according to the time interval between ESWL and ERCP, including the same day (\< 12 hours) subgroup and the next day ( ≥12 hours) subgroup. The cannulation success rate and stone clearance rate of the pancreatic duct will be assessed in each group to explore the most appropriate timing of ERCP, and then provide an important reference basis for the clinical treatment of chronic pancreatitis.
AIMS: Pulmonary arterial hypertension (PAH) is characterized by extensive pulmonary arterial remodelling. Although mesenchymal stem cell (MSC)-derived exosomes provide protective effects in PAH, MSCs exhibit limited senescence during in vitro expansion compared with the induced pluripotent stem cells (iPSCs). Moreover, the exact mechanism is not known.
METHODS AND RESULTS: In this study, we used murine iPSCs generated from mouse embryonic fibroblasts with triple factor (Oct4, Klf4, and Sox2) transduction to determine the efficacy and action mechanism of iPSC-derived exosomes (iPSC-Exo) in attenuating PAH in rats with monocrotaline (MCT)-induced pulmonary hypertension. Both early and late iPSC-Exo treatment effectively prevented the wall thickening and muscularization of pulmonary arterioles, improved the right ventricular systolic pressure, and alleviated the right ventricular hypertrophy in MCT-induced PAH rats. Pulmonary artery smooth muscle cells (PASMC) derived from MCT-treated rats (MCT-PASMC) developed more proliferative and pro-migratory phenotypes, which were attenuated by the iPSC-Exo treatment. Moreover, the proliferation and migration of MCT-PASMC were reduced by iPSC-Exo with suppression of PCNA, cyclin D1, MMP-1, and MMP-10, which are mediated via the HIF-1α and P21-activated kinase 1/AKT/Runx2 pathways.
CONCLUSION: IPSC-Exo are effective at reversing pulmonary hypertension by reducing pulmonary vascular remodelling and may provide an iPSC-free therapy for the treatment of PAH.
Cervical cancer is a significant health concern for women worldwide, with human papillomavirus (HPV) being the primary cause. This study aimed to assess Saudi women's awareness and knowledge of HPV, determine their information sources, and evaluate their intention to receive the HPV vaccine. A questionnaire-based survey was conducted among 654 Saudi females aged 18 to 60 years from January to May 2023. The results revealed that 60.85% of the participants had heard about HPV, but only 8.25% had received the HPV vaccination. Despite the low vaccination rate, 71.11% of the respondents expressed willingness to receive the vaccine. Educational level was the significant predictor of the vaccine awareness and acceptance. The internet and social media were the most prevalent sources of information about HPV. The study highlights the need for additional education about HPV-related diseases and vaccination among Saudi women. Although there is a high level of HPV vaccine acceptance, the lack of knowledge suggests that targeted educational interventions are necessary to increase awareness and promote vaccination uptake. These findings can inform public health strategies to reduce the burden of cervical cancer in Saudi Arabia through improved HPV vaccination coverage and education.
This study is a prospective, longitudinal observational study of patients with newly diagnosed or relapsed/refractory T-cell and NK-cell neoplasms, conducted across multiple participating institutions globally. Patients will be enrolled during their initial visit as new patients and will be followed for up to four years through the course of their clinical management. Data for routine demographics, baseline clinical features, including pathology, molecular information related to the tumor, radiology, treatment characteristics and quality of life (QoL) associated with their lymphoma care will be collected over the course of 4 years by clinical research teams at every participating institution. The de-identified data will be securely shared through a password protected REDCap with other participating institutions under data usage agreements of the consortium. Next generation sequencing (NGS) including but not limited to whole exome sequencing and bulk RNA-sequencing will be performed on archived lymphoma specimens, mononuclear cells, cfDNA and saliva (when feasible) for a comprehensive molecular characterization of the tumor. Molecular data will be analyzed in correlation with patient outcomes. Advanced deep learning algorithms will be applied to predict responses and survival across lymphoma subtypes, heterogeneous clinical scenarios and various potential therapeutic approaches that the patient has not been exposed to.